Ascentage Pharma Group International ADR | Mid-cap | Healthcare
$39.86
1.22%
| Ascentage Pharma Stock Comparison:
Ascentage Pharma vs VertexAscentage Pharma vs RegeneronAscentage Pharma vs MadrigalAscentage Pharma vs Bio-TechneAscentage Pharma vs Corcept TherapeuticsAscentage Pharma vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 427.8M
Total Liabilities 332.9M
Shareholders Equity 94.9M
Debt to Equity 3.51

Cash Flow Metrics

Revenue & Profitability Trend

Ascentage Pharma Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i137.7M31.2M29.4M27.9M12.4M
Cost of Goods Sold i4.1M4.3M3.1M3.3M2.0M
Gross Profit i133.6M26.9M26.4M24.6M10.5M
Gross Margin % i97.0%86.2%89.5%88.1%84.2%
Operating Expenses
Research & Development i133.0M99.3M104.3M766.5M564.6M
Selling, General & Administrative i53.8M52.9M46.0M191.3M64.1M
Other Operating Expenses i-1.3M-2.7M-4.7M--
Total Operating Expenses i185.6M149.4M145.6M957.8M628.6M
Operating Income i-51.9M-122.6M-119.3M-869.8M-663.9M
Operating Margin % i-37.7%-393.1%-405.2%-3,116.6%-5,332.9%
Non-Operating Items
Interest Income i5.3M4.6M1.4M7.1M5.2M
Interest Expense i9.1M13.5M7.4M16.7M6.3M
Other Non-Operating Income153.1K480.6K799.6K--
Pre-tax Income i-55.5M-131.0M-124.5M-832.2M-675.4M
Income Tax i1.5M-1.0M-596.3K-49.8M2.2M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-57.0M-130.0M-123.9M-782.4M-677.6M
Net Margin % i-41.4%-417.0%-421.0%-2,803.4%-5,442.6%
Key Metrics
EBITDA i-34.2M-105.0M-109.6M-847.9M-638.0M
EPS (Basic) i$-5.36$-13.12$-13.40$-3.07$-3.14
EPS (Diluted) i$-5.36$-13.12$-13.40$-3.07$-3.14
Basic Shares Outstanding i106061129912192925392818554836971573610657
Diluted Shares Outstanding i106061129912192925392818554836971573610657

Income Statement Trend

Ascentage Pharma Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i173.7M150.2M207.1M1.7B1.0B
Short-term Investments i-----
Accounts Receivable i11.7M20.5M7.6M54.0M0
Inventory i926.5K2.3M1.3M3.9M0
Other Current Assets-----
Total Current Assets i207.0M188.8M229.7M1.9B1.1B
Non-Current Assets
Property, Plant & Equipment i0091.1M9.9M1.9M
Goodwill i17.6M18.9M18.8M109.8M146.8M
Intangible Assets i10.7M12.0M11.8M60.4M97.4M
Long-term Investments-----
Other Non-Current Assets14.2M9.4M8.7M45.8M52.1M
Total Non-Current Assets i160.6M162.4M167.6M1.1B652.0M
Total Assets i367.7M351.2M397.3M2.9B1.7B
Liabilities
Current Liabilities
Accounts Payable i12.9M10.2M13.4M70.9M23.4M
Short-term Debt i109.4M86.6M72.8M49.5M50.6M
Current Portion of Long-term Debt-----
Other Current Liabilities--396.1K-10.1M
Total Current Liabilities i163.8M131.2M123.7M361.1M276.1M
Non-Current Liabilities
Long-term Debt i124.9M165.6M178.9M1.0B479.1M
Deferred Tax Liabilities i753.9K1.5M1.7M13.8M15.4M
Other Non-Current Liabilities881.2K----
Total Non-Current Liabilities i165.3M210.1M216.2M1.3B608.3M
Total Liabilities i329.2M341.3M339.9M1.7B884.4M
Equity
Common Stock i30.1K27.7K25.3K178.0K154.0K
Retained Earnings i-810.5M-753.5M-623.2M-3.6B-2.8B
Treasury Stock i1.1K3.0M3.7M3.0K4.0K
Other Equity-----
Total Shareholders Equity i38.5M9.9M57.4M1.2B846.6M
Key Metrics
Total Debt i234.3M252.2M251.7M1.1B529.7M
Working Capital i43.2M57.6M106.0M1.5B802.9M

Balance Sheet Composition

Ascentage Pharma Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-55.5M-131.0M-124.5M-832.2M-675.4M
Depreciation & Amortization i13.1M13.1M8.8M--
Stock-Based Compensation i2.9M4.4M3.1M47.0M74.0M
Working Capital Changes i6.6M-7.0M6.2M142.0M-1.8M
Operating Cash Flow i-23.9M-107.0M-99.1M-608.7M-575.1M
Investing Activities
Capital Expenditures i-3.4M-6.5M-28.2M-435.1M-249.9M
Acquisitions i-3.6M-2.8M-2.8M-36.2M0
Investment Purchases i---18.2M-1.8B-2.2B
Investment Sales i--01.8B2.3B
Investing Cash Flow i-7.0M-9.3M-49.3M-465.3M33.7M
Financing Activities
Share Repurchases i0-831.9K-3.8M-25.9M0
Dividends Paid i000--
Debt Issuance i75.3M133.9M107.2M599.7M527.8M
Debt Repayment i-95.7M-135.8M-9.5M-51.2M-95.0M
Financing Cash Flow i52.7M64.8M93.9M1.8B1.1B
Free Cash Flow i-19.1M-110.0M-125.1M-1.0B-861.4M
Net Change in Cash i21.9M-51.5M-54.4M749.4M523.5M

Cash Flow Trend

Ascentage Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -7.35
Forward P/E 24.98
Price to Book 20.32
Price to Sales 9.50

Profitability Ratios

Profit Margin -296.77%
Operating Margin -237.05%
Return on Equity -159.65%
Return on Assets -22.77%

Financial Health

Current Ratio 1.54
Debt to Equity 253.91
Beta 0.87

Per Share Data

EPS (TTM) $-2.04
Book Value per Share $1.94
Revenue per Share $4.78

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
aapg3.5B-7.3520.32-159.65%-296.77%253.91
Vertex 103.4B28.686.0222.77%31.86%8.89
Regeneron 63.8B15.132.0915.34%31.37%9.04
Madrigal 9.9B-20.2314.14-36.30%-54.68%17.81
Bio-Techne 9.8B136.855.083.68%6.02%23.14
Corcept Therapeutics 9.3B78.7114.6021.70%18.67%1.04

Financial data is updated regularly. All figures are in the company's reporting currency.